Thymosin Alpha-1 (Tα1) is a synthetic 28-amino-acid peptide supplied as a lyophilized powder for controlled laboratory research, analytical testing, and in vitro experimentation.
Laboratories may evaluate Thymosin Alpha-1 through peptide identity analysis, molecular-interaction studies, receptor-associated assays, cytokine-associated measurements, and gene-expression testing. All observations must remain limited to the selected experimental model, methodology, controls, and analytical endpoints.
Lot-specific analytical documentation is available through the Nordsci Certificate of Analysis Library.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Thymosin Alpha-1 is a synthetic peptide research material corresponding to a defined 28-amino-acid sequence. It is supplied as a lyophilized powder in 3mg and 10mg vial sizes for laboratory research, analytical characterization, and controlled in vitro experimentation.
Research applications may include peptide identity testing, molecular-interaction analysis, cell-based assay development, receptor-associated measurements, cytokine-associated marker analysis, and gene-expression testing. References to thymic-derived or immune-cell-derived laboratory systems describe experimental models and measurable endpoints only.
Results obtained from these systems do not establish safety, effectiveness, clinical utility, or an effect on human or animal physiology.
Thymosin Alpha-1 (3/10mg) – Research Specifications:
| Compound | Thymosin Alpha-1 (Tα1) |
| Unit Size | 3mg or 10mg per vial |
| Unit Quantity | 1 vial |
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Molecular Formula | C129H215N33O55 |
| Molecular Weight | Approximately 3108.3 g/mol |
| CAS Number | 62304-98-7 |
| Compound Type | Synthetic peptide research material |
| Form | Lyophilized powder |
| Source | Chemical synthesis |
| Purity and Identity | Refer to the applicable lot-specific Certificate of Analysis |
| Analytical Documentation | May include HPLC, mass spectrometry, or other reported analytical results |
| Storage Conditions | Store sealed at −20°C or below and protect from light, heat, and moisture unless otherwise stated in the applicable documentation |
| Research Classification | Laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption or for in vivo, diagnostic, therapeutic, food, drug, cosmetic, or dietary-supplement use |
Thymosin Alpha-1 is a synthetic 28-amino-acid peptide corresponding to a sequence originally identified during the analytical study of thymic peptide fractions. Synthetic production gives laboratories access to a defined research material suitable for controlled analytical and in vitro methods.
Laboratory research may examine Thymosin Alpha-1 in selected cellular assay systems. Researchers can establish predefined endpoints such as peptide identity, molecular binding, receptor-associated measurements, transcription-associated markers, cell-surface markers, or cytokine-associated analytes.
These measurements characterize observations within a controlled experimental system. They do not establish an effect on immunity, infection, inflammation, disease, vaccination, or any other human or animal outcome.
Experimental interpretation should account for the selected cell type, assay format, concentration range, exposure period, controls, sample-processing conditions, analytical platform, and predefined acceptance criteria. Findings should remain limited to the methods and endpoints used in the study.
Important Research Notice: Nordsci research materials include access to lot-specific analytical documentation. Consult the applicable Certificate of Analysis for reported identity, purity, and testing information.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR DIETARY-SUPPLEMENT USE.
Thymosin Alpha-1 may be evaluated in controlled in vitro systems containing T-cell-derived or other immune-cell-derived laboratory models. Researchers can measure predefined cellular and molecular markers under documented experimental conditions.
Any observed response remains specific to the selected model, assay method, controls, and analytical endpoints. It must not be interpreted as evidence of an effect on human or animal immune function.
Laboratories may use Thymosin Alpha-1 in assays designed to measure selected cytokine-associated analytes. Study plans should define the target analytes, reference controls, sampling intervals, analytical platform, and acceptance criteria before testing begins.
A measured change in a cytokine-associated analyte does not independently demonstrate anti-inflammatory, antimicrobial, antiviral, immunostimulatory, or therapeutic activity.
Researchers may examine selected cell-surface or gene-expression-associated markers following exposure to Thymosin Alpha-1 within a controlled in vitro model. Test conditions can be compared with untreated, vehicle, baseline, or other suitable laboratory controls.
Observed differences remain limited to the selected assay system. They do not establish clinical relevance or effects on infection, inflammation, vaccination, disease, or other human or animal outcomes.
Thymosin Alpha-1 may be compared with other thymic peptide research materials, including Thymalin, through standardized analytical or in vitro methods.
Comparative experiments can evaluate differences in peptide identity, analytical characteristics, molecular interactions, or assay-specific marker measurements. Conclusions should account for model variability, controls, testing methodology, and the limitations of the selected analytical platform.
Thymosin Alpha-1 should be handled exclusively by qualified laboratory personnel using established procedures for synthetic peptide research materials. Laboratories should document product receipt, lot identification, storage conditions, sample allocation, analytical methods, testing results, and disposal.
This product information does not provide preparation, concentration, dosing, injection, administration, application, or in vivo instructions.
Protocol Design Considerations:
Note: This information is provided exclusively as a laboratory research reference. All work must be conducted by qualified personnel in appropriately equipped facilities.
Lot-specific Certificates of Analysis provide analytical information for the applicable Thymosin Alpha-1 product lot. Reported documentation may include identity, purity, analytical methodology, mass confirmation, chromatographic results, and other lot-specific findings.
Researchers should verify that the lot number printed on the product vial corresponds with the lot number shown on the applicable COA. Analytical results apply exclusively to the tested lot and do not establish clinical safety, effectiveness, regulatory approval, or suitability for human or veterinary use.
Nordsci Peptides supplies Thymosin Alpha-1 in 3mg and 10mg vial sizes as a synthetic laboratory research material. Each product lot includes access to applicable analytical documentation through the Nordsci COA Library.
Qualified laboratories should review product identity, lot-specific analytical results, storage requirements, batch traceability, and institutional procurement standards before acquiring the material.
IMPORTANT: Thymosin Alpha-1 is sold exclusively for laboratory research and analytical use. It is not a drug, food, dietary supplement, cosmetic, or therapeutic product. It is not approved for human or veterinary use and must not be used for consumption, diagnosis, treatment, prevention, compounding, or any in vivo procedure.
